Abstract PO3-25-09: OKI-219, a PI3KαH1047R-mutant-selective Inhibitor Demonstrates Efficacy As a Single Agent and Drives Combination Responses with Standard of Care Therapies in Pre-Clinical PI3KαH1047R Mutant Breast Cancer Models
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined